

10806370

10-15

- (18) Replace the paragraph at page 6, lines ~~20-25~~ with the following substitute paragraph.

A further embodiment of the invention is a pharmaceutical composition comprising an expression vector and a pharmaceutically acceptable carrier. The expression vector encodes a polypeptide comprising an amino acid sequence selected from the group consisting of (a) the amino acid sequence shown in SEQ ID NO:12, (b) the amino acid sequence encoded by a cDNA insert contained within plasmid pCRII-TMSP3 (ATCC Accession No. [[____]] PTA-3433), and (c) biologically active variants thereof.

lines 16-26

- (19) Replace the paragraph at page 6, ~~line 26 to page 7, line 7~~ with the following substitute paragraph.

Still another embodiment of the invention is a method of treating a disorder selected from the group consisting of chronic obstructive pulmonary disease, cancer, metastasis of malignant cells, tumor angiogenesis, inflammation, atherosclerosis, neurodegenerative diseases, and pathogenic infections. A therapeutically effective dose of a reagent that inhibits a function of a human transmembrane serine protease is administered to a patient in need thereof. The human transmembrane serine protease comprises an amino acid sequence selected from the group consisting of (a) the amino acid sequence shown in SEQ ID NO:12, (b) the amino acid sequence encoded by a cDNA insert contained within plasmid pCRII-TMSP3 (ATCC Accession No. [[____]] PTA-3433), and (c) biologically active variants thereof. Symptoms of the disorder are thereby ameliorated.

CF
9.20.07